Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

4 recruiting2 with results

Enrollment Performance

Analytics

N/A
6(46.2%)
Phase 2
3(23.1%)
Phase 1
2(15.4%)
Phase 4
1(7.7%)
Early Phase 1
1(7.7%)
13Total
N/A(6)
Phase 2(3)
Phase 1(2)
Phase 4(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT07383142Not ApplicableNot Yet Recruiting

Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence (CHOICE-2)

Role: collaborator

NCT07169916Not ApplicableNot Yet Recruiting

Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer

Role: collaborator

NCT06876584Completed

The CT-based Deep Learning Model Predicts Complications in Partial Nephrectomy

Role: collaborator

NCT05431621Completed

Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers

Role: collaborator

NCT06451783Early Phase 1Enrolling By Invitation

Shengyu Decoction and Lijin Manipulation for Knee OA: 3D Gait Analysis

Role: lead

NCT06329999Not ApplicableRecruiting

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Role: collaborator

NCT05818735Not ApplicableRecruiting

Effect of Electroacupuncture on Treating the First-episode Depression

Role: collaborator

NCT05987826Phase 2Unknown

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Role: collaborator

NCT05001113Not ApplicableCompleted

Surgery for Masaoka-Koga I-II Thymoma

Role: collaborator

NCT04973306Phase 2Recruiting

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

Role: collaborator

NCT04062500Recruiting

Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure

Role: collaborator

NCT04506281Phase 2Unknown

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Role: collaborator

NCT02897713Not ApplicableSuspended

Feasibility, Safety, and Outcomes of Intensive Enteral Nutrition in Patients With Mechanical Ventilation

Role: collaborator

NCT04398251Phase 4Unknown

A Randomized Clinical Trail of The Effect of Postoperative Uric Acid Control on Stone Recurrence and Renal Function in Patients With Hyperuricemia of Urolithiasis.

Role: lead

NCT02174523Phase 1Completed

Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects

Role: collaborator

NCT02174510Phase 1Completed

A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

Role: collaborator

All 16 trials loaded